Dr. John Iafrate is the Deputy Chair of Pathology at Mass General Hospital and Professor of Pathology at Harvard University. He has been a leader in developing and implementing diagnostic technologies in the fields of genomics and transcriptomics. As a post-doctoral research fellow at Brigham and Women’s Hospital he discovered germline copy number variation utilizing DNA microarrays. As a principal investigator at MGH, his laboratory helped usher in the era of multiplexed genotyping, culminating with the development of Anchored Multiplex PCR for targeted DNA and RNA sequencing. He collaborated with Dr. Joung in the application of the technology to CRISPR off-target assessment (GUIDE-seq). He has been integrally involved in the development of personalized medicine in cancer, including for ALK and ROS1-positive lung cancers. John is a serial entrepreneur who founded ArcherDx (acquired by Enzymatics), Boston Lighthouse (a cancer genomic software platform company acquired by Oncoclincas Brasil), and Hunter Biodiscovery.